Hansa Biopharma AB (publ)
SSE:HNSA.ST
Overview | Financials
Company Name | Hansa Biopharma AB (publ) |
Symbol | HNSA.ST |
Currency | SEK |
Price | 32.64 |
Market Cap | 1,719,207,552 |
Dividend Yield | 0% |
52-week-range | 20.14 - 58.1 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Søren Tulstrup M.Sc |
Website | https://www.hansabiopharma.com |
An error occurred while fetching data.
About Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD